Last reviewed · How we verify
Cefazolin / Vancomycin
Cefazolin and vancomycin are bactericidal antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and D-Ala-D-Ala residues, respectively.
Cefazolin and vancomycin are bactericidal antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and D-Ala-D-Ala residues, respectively. Used for Surgical site infection prophylaxis, Serious gram-positive bacterial infections, Methicillin-resistant Staphylococcus aureus (MRSA) infections.
At a glance
| Generic name | Cefazolin / Vancomycin |
|---|---|
| Also known as | Ancef, Vancin |
| Sponsor | University of Cincinnati |
| Drug class | Beta-lactam antibiotic / Glycopeptide antibiotic |
| Target | Penicillin-binding proteins / D-Ala-D-Ala peptidoglycan precursors |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Cefazolin is a first-generation cephalosporin that inhibits cross-linking of peptidoglycan in the bacterial cell wall. Vancomycin is a glycopeptide antibiotic that binds to D-Ala-D-Ala precursors and prevents cell wall synthesis. Together, this combination provides broad-spectrum coverage against gram-positive bacteria and is commonly used for surgical prophylaxis and serious infections.
Approved indications
- Surgical site infection prophylaxis
- Serious gram-positive bacterial infections
- Methicillin-resistant Staphylococcus aureus (MRSA) infections
Common side effects
- Hypersensitivity reactions (rash, urticaria)
- Nephrotoxicity
- Ototoxicity
- Phlebitis at injection site
- Nausea/vomiting
Key clinical trials
- IO Vancomycin Spine (PHASE2, PHASE3)
- Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial (PHASE4)
- Local Antibiotics for Breast Implants (PHASE3)
- Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia (PHASE4)
- Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial (PHASE4)
- Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO) (NA)
- IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA (NA)
- Antibiotic Concentrations Among Critically Ill Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cefazolin / Vancomycin CI brief — competitive landscape report
- Cefazolin / Vancomycin updates RSS · CI watch RSS
- University of Cincinnati portfolio CI